NEW YORK (
) - Shares of the following
Dow Jones Industrial Average
all hit 52-week highs on Monday.
Each of these stocks received a buy rating from
"Europe was KO's largest operating profit contributor in 2011, but faces a tough 2012 due to weak economies, bottler pricing, French taxes, and FX," JPMorgan analysts wrote in a March 12 report. The analysts added, "The stock has underperformed the market and staples for the past 5 months, so we see limited downside from here."
Shares of Coca-Cola hit a 52-week high of $71.89 Monday. The stock's 52-week low of $63.34 was set on Oct. 4.
Coca-Cola's stock trades at an estimated price-to-earnings ratio for next year of 16.04 times; the average for soft drink companies is 18.33X. For comparison,
has a lower forward P/E of 14.83X.
Nineteen of the 24 analysts who cover Coca-Cola rate it at buy; five analysts give the stock a hold rating.
gives Coca-Cola an A grade with a buy rating and
price target. The stock has risen 2.73% year to date.
"In July 2011, Pfizer announced a strategic review of the options for its Nutritionunit," Bank of America Merrill Lynch analysts wrote in a report Monday. "In our view, a sale remains the most likely outcome although Pfizer could still choose a spin-off to alleviate tax or anti-trust concerns. Recent press reports state second round bids were due on 5th March and it would appear that the auction process is now drawing to a close. Indicative pricing appears near the top of the $8-10bn range implying 4-5x 2012E sales of $2.2bn (BofAMLe) or ~18x EBITDA assuming a 25% margin, in-line with previous baby food deals including Nestle- Gerber (16x) and Danone-Numico (22x). If anti-trust and tax concerns are satisfied, we believe Pfizer may announce a sale of the unit as early as end 1H12."
Shares of Pfizer hit a 52-week high Monday of $22.26. The stock's 52-week low of $16.63 was set on Aug. 9.
Pfizer's stock trades at a forward P/E is 9.46X; the average for pharmaceutical companies is 32.52. For comparison, both
have higher forward P/Es of 10.4X and 17.3X, respectively.
Twenty-one of the 27 analysts who cover Pfizer rate it at buy. Four analysts have a hold rating on the stock and two rate it at sell.
gives Pfizer an A- grade with a buy rating and
price target. The stock has risen 2.61% year to date.
"We expect DIS' F2Q results to reflect underlying strength at Media Networks andParks, partially offset by impaired Film due to the lackluster performance of John Carter (incurring a $200mn write-down in the Q)," Bank of America Merrill Lynch analysts wrote in a March 22 report. "More specifically, F2Q should benefit from: (1) healthy underlying national advertising trends, (2) solid affiliate fees, (3) improved attendance trends at Parks (with reduced discounting), (4) easier comps for Tokyo Disneyland (following F2Q11's earthquake drag of $25mn) and (5) Oprah cost savings at TV. Key offsets: (1) a pre-announced $80- 120mn loss at Studio (we est. a loss of $112mn), (2) Fantasy pre-launch costs, (3) 20 hours of additional ABC Family programming (+$35mn), (4) Japan channel launch costs (+$17.5mn) and (5) 9 more NBA games at ESPN."
Shares of Walt Disney hit a 52-week high Monday of $44.30. The stock's 52-week low of $28.19 was set on Oct. 4.
Walt Disney shares trade at a forward P/E of 13X; the average for broadcasting and entertainment companies is 31.46X. For comparison, both
have lower forward P/Es of 11.87X and 11.86X, respectively.
Twenty of the 34 analysts who cover Walt Disney rate it at buy; 14 analysts give the stock a hold rating.
gives Walt Disney an A+ grade with a buy rating and
price target. The stock has risen 17.81% year to date.
Written by Alexandra Zendrian in New York.
>To contact the writer of this article, click here:
>To submit a news tip, send an email to:
>To follow the writer on Twitter, go to